company background image
GIS

Gilead Sciences DB:GIS Stock Report

Last Price

€74.35

Market Cap

€96.6b

7D

-2.6%

1Y

29.2%

Updated

02 Feb, 2023

Data

Company Financials +

GIS Stock Overview

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally.

GIS fundamental analysis
Snowflake Score
Valuation2/6
Future Growth2/6
Past Performance0/6
Financial Health3/6
Dividends2/6

My Notes

New

Notes are coming soon

Gilead Sciences, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Gilead Sciences
Historical stock prices
Current Share PriceUS$74.35
52 Week HighUS$84.73
52 Week LowUS$52.23
Beta0.43
1 Month Change-8.45%
3 Month Change-7.90%
1 Year Change29.17%
3 Year Change19.92%
5 Year Change12.82%
Change since IPO446.99%

Recent News & Updates

Recent updates

Shareholder Returns

GISDE BiotechsDE Market
7D-2.6%-2.4%3.4%
1Y29.2%6.9%-8.2%

Return vs Industry: GIS exceeded the German Biotechs industry which returned 4.5% over the past year.

Return vs Market: GIS exceeded the German Market which returned -11.7% over the past year.

Price Volatility

Is GIS's price volatile compared to industry and market?
GIS volatility
GIS Average Weekly Movement3.1%
Biotechs Industry Average Movement5.6%
Market Average Movement5.2%
10% most volatile stocks in DE Market10.4%
10% least volatile stocks in DE Market2.3%

Stable Share Price: GIS is less volatile than 75% of German stocks over the past 3 months, typically moving +/- 3% a week.

Volatility Over Time: GIS's weekly volatility (3%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
198714,400Dan O'Dayhttps://www.gilead.com

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients.

Gilead Sciences, Inc. Fundamentals Summary

How do Gilead Sciences's earnings and revenue compare to its market cap?
GIS fundamental statistics
Market Cap€96.56b
Earnings (TTM)€3.06b
Revenue (TTM)€24.87b

30.6x

P/E Ratio

3.8x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
GIS income statement (TTM)
RevenueUS$27.14b
Cost of RevenueUS$5.64b
Gross ProfitUS$21.50b
Other ExpensesUS$18.16b
EarningsUS$3.33b

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)2.66
Gross Margin79.22%
Net Profit Margin12.29%
Debt/Equity Ratio119.8%

How did GIS perform over the long term?

See historical performance and comparison

Dividends

3.6%

Current Dividend Yield

109%

Payout Ratio